INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. (CAPR) Announced by Holzer & Holzer, LLC

ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 11, 2025, Capricor announced that it had received a Complete Response Letter (“CRL”) from the FDA regarding its Biologics License Application (“BLA”) for Deramiocel. Following this news, the price of the Company’s stock dropped. If you purchased Capricor stock and suffered a loss on that investment, y ...